Real examples from recent studies illustrate the risks associated with making such a delicate decision.
Peter Kleist
Advertisement
Peter Kleist, MD, MFPM RCP-UK, is a specialist in pharmaceutical medicine (CH) and medical director, Novartis Pharma Schweiz AG, Suedbahnhofstrasse 14d, CH-3007 Bern, Switzerland, email: peter.kleist@pharma.novartis.com.
Articles by Peter Kleist
Adequate female representation is mandatory, but gender differences should not be overestimated.
Advertisement
Latest Updated Articles
Stopping a Trial Early for Treatment Benefit: Pros & ConsPublished: January 1st 2007 | Updated:
Women and Trials: When Is Gender a Consideration?Published: June 1st 2005 | Updated:
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Reducing Site Burden Through Better Technology Integration in Clinical Trials
2
ACT Brief: AI, Equity, and Innovation Drive Clinical Research Forward
3
MATTERHORN Trial Findings Signal Paradigm Shift in Early Gastric Cancer Care
4
ACT Brief: AstraZeneca Expands Immunotherapy Reach as Thermo Fisher’s $8.8B Deal Signals New Phase for Digital Trials
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
